Drug Profile

Belapectin - Galectin Therapeutics

Alternative Names: Galactoarabino-rhamnogalaturonate; GR MD 02

Latest Information Update: 29 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Galectin Therapeutics
Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antipsoriatics; Carbohydrates; Hepatoprotectants; Polysaccharides; Skin disorder therapies; Small molecules
Mechanism of Action Galectin 3 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Head and neck cancer; Lung cancer; Malignant melanoma; Non-alcoholic steatohepatitis; Orofacial cancer; Portal hypertension

Phase II/III Liver cirrhosis
Phase II Atopic dermatitis; Hepatic fibrosis; Plaque psoriasis
No development reported Breast cancer; Cardiac-arrhythmias; Diabetic nephropathies; Fibrosis; Head and neck cancer; Lung cancer; Malignant melanoma; Orofacial cancer; Prostate cancer; Pulmonary arterial hypertension; Pulmonary fibrosis; Renal fibrosis
Discontinued Non-alcoholic steatohepatitis

23 Jun 2026 Belapectin - Galectin Therapeutics is available for licensing as of 23 Jun 2026. http://www.galectintherapeutics.com
23 Jun 2026 Galectin Therapeutics announces positive Type C meeting outcome with the US FDA for Belapectin in patients with MASH cirrhosis and Portal hypertension
23 Jun 2026 Galectin plans to submit phase III clinical trial protocol for patients with Metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and Portal hypertension in Q3 2026

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com